@berad “Little knowledge is more dangerous “.
True it is. I am not of business background but a mere clinician with experience in the area, so I should just trust that the company is doing what’s best.......or I could research the area and understand the science. Path to market for MsC in GVHD is quick, we know the cells work, MSB have proven that. Explain to me again why Someone else’s cells won’t? I reiterate again; it’s a risky proposition for a large pharma to sink money into a product which is likely to bet superceded in 2 years, hence partner and a bad debt facility. Sure Fuji haven’t signed the dotted line, but they have invested so if to works (proven), and it’s safe why wouldn’t they?
